Ongoing Research on Targeted Therapy in Relapsed/Refractory CLL

EP: 1.Looking Ahead to Upcoming Presentations at ASH 2023

EP: 2.Targeted Therapy and Role of Biomarkers in B-Cell Malignancies

EP: 3.CLL: Updated Data in the Frontline Setting Presented at ASH 2023

EP: 4.Zanubrutinib Plus Sonrotoclax in Patients With Treatment-Naïve CLL/SLL

EP: 5.Recent Data in Relapsed/Refractory CLL/SLL

EP: 6.Adverse Events for BTK Inhibitors and BCL2 Inhibitors in CLL

EP: 7.Treatment Sequencing for Patients With B-Cell Malignancies

Now Viewing

EP: 8.Ongoing Research on Targeted Therapy in Relapsed/Refractory CLL

EP: 9.Future of Treatment of B-Cell Malignancies

This is a video synopsis/summary of an Insights featuring: Nicole Lamanna, MD.

In this segment, Dr. Lamanna discusses updated data at the 2023 American Society of Hematology (ASH) annual meeting from the BRUIN study of the non-covalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia (CLL) who progressed after prior covalent BTK inhibitors and sometimes B-cell lymphoma 2 (BCL2) inhibitors as well.

With over 30 months of follow-up, the median progression-free survival with pirtobrutinib reached 19 months, showing durable efficacy in this relapsed/refractory population. Ongoing assessment for adverse events over time is important for BTK inhibitors, but pirtobrutinib continues to demonstrate a tolerable safety profile, with less than 3% discontinuation rate due to adverse events at 30 months.

Dr. Lamanna highlights this updated data for a non-covalent BTK inhibitor in patients failing standard therapies provides an exciting new treatment option for these patients. Having these agents on guidelines facilitates patient access and ability to implement sequencing strategies as the treatment landscape evolves.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.